How GLP-1 Peptides Work for Weight Loss

GLP-1 receptor agonists — the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — represent the most significant advance in obesity pharmacotherapy in a generation. The weight loss results from clinical trials are, by historical standards, remarkable. And yet, for most people, exactly how these drugs work remains unclear.

Understanding the mechanism isn't just academically interesting — it has practical implications for who responds to treatment, what side effects to expect and why, how to get the most from a protocol, and what happens if you stop. This guide explains the full picture in plain language, grounded in the clinical evidence.

What GLP-1 Actually Is

GLP-1 stands for glucagon-like peptide-1. It is a hormone produced naturally by specialised L-cells in the lining of the small intestine in response to food — particularly carbohydrates and fats. Under normal physiology, your body releases a pulse of GLP-1 after a meal, and this hormone plays a central role in signalling satiety and regulating blood sugar.^[1]

The problem with naturally occurring GLP-1 is that it has a very short half-life — it is broken down by an enzyme called dipeptidyl peptidase-4 (DPP-4) within 1–2 minutes of being released. This means its effects are transient, and it cannot be used therapeutically in its natural form.

GLP-1 receptor agonists solve this problem by using synthetic peptides that are structurally similar to GLP-1 but chemically modified to resist DPP-4 degradation. This gives them half-lives measured in days rather than minutes — long enough to produce sustained effects when administered as a once-weekly injection.

The Four Mechanisms Behind Weight Loss

GLP-1 receptor agonists produce their weight loss effects through four distinct but interconnected mechanisms. Understanding all four is important — because each has different practical implications for the patient experience.

Together, these four mechanisms produce a caloric deficit not primarily through hunger suppression alone, but through a fundamental shift in the body's appetite, satiety, and metabolic signalling. This is a qualitatively different experience from traditional calorie restriction — which is why patients on GLP-1 agonists frequently describe reduced food noise and spontaneous portion reduction rather than the effortful restriction associated with conventional dieting.^[2]

What the Clinical Trials Show

GLP-1 receptor agonists have been evaluated in some of the largest and most rigorously conducted weight management trials ever conducted. The results are not subtle.

To contextualise these numbers: prior to GLP-1 agonists, pharmacological obesity treatments rarely achieved more than 5–8% body weight reduction. Bariatric surgery — the most effective intervention available — typically produces 25–30% weight loss. Semaglutide and tirzepatide sit in a range previously only accessible surgically.^[3]

The STEP 1 trial (semaglutide 2.4mg vs placebo in adults with obesity without diabetes) showed a mean weight loss of 14.9% at 68 weeks, with 69% of participants losing at least 10% of body weight and 50% losing at least 15%. The SURMOUNT-1 trial (tirzepatide vs placebo) showed mean weight loss of up to 22.5% at 72 weeks, with 57% of participants achieving at least 20% weight loss.^[4]

Semaglutide vs Tirzepatide: What's the Difference?

Both are GLP-1-based therapies, but they differ in an important way: semaglutide is a pure GLP-1 receptor agonist, while tirzepatide is a dual agonist that also targets the GIP (glucose-dependent insulinotropic polypeptide) receptor.

GIP is another gut hormone involved in insulin secretion and fat metabolism. By targeting both GLP-1 and GIP receptors simultaneously, tirzepatide produces a more potent combined effect on appetite, satiety, and metabolic function — which is the primary reason its weight loss outcomes exceed those of semaglutide in head-to-head comparisons.^[5]

For most patients, tirzepatide currently produces superior weight loss outcomes. However, semaglutide has a longer cardiovascular safety track record — the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease. Both remain first-line options, and the choice between them depends on individual clinical circumstances, tolerability, and access.^[6]

Beyond Weight Loss: The Broader Metabolic Benefits

GLP-1 receptor agonists produce effects well beyond the scale. Because GLP-1 receptors are distributed throughout the body — including in the heart, kidneys, liver, and brain — these medications have metabolic and organ-protective effects that are increasingly recognised as clinically significant in their own right.

The Lean Mass Question: An Important Nuance

One finding from recent research warrants honest discussion: approximately 25–45% of total weight loss with semaglutide and tirzepatide comes from reductions in lean body mass (muscle), not just fat.^[7]

This is not unique to GLP-1 agonists — the same proportion of lean mass loss is seen with lifestyle-based weight loss interventions. However, it does have practical implications. Loss of lean mass can reduce metabolic rate, affect physical function, and — particularly in older adults or those with existing low muscle mass — compound existing risk factors.

The mitigation is well-established and straightforward: resistance training and adequate protein intake (typically 1.6–2.2g per kilogram of body weight daily) significantly preserve lean mass during GLP-1 treatment. Clinicians prescribing these medications should address both — and patients should treat exercise and nutrition as integral components of the protocol, not optional additions.

Side Effects: What to Expect

The side effect profile of GLP-1 receptor agonists is well-characterised from large clinical trials. Most side effects are gastrointestinal and are directly related to the gastric-emptying mechanism. They are most common when starting the medication or during dose increases, and typically diminish over time.^[3]

Managing GI side effects: Nausea is most effectively managed by starting at a low dose and increasing slowly, eating smaller meals, avoiding high-fat foods, and staying well hydrated. Most patients find GI symptoms significantly reduce after the first 4–8 weeks once the body adapts to the medication.

Who Should Not Use GLP-1 Agonists

The Weight Regain Reality: What Happens When You Stop

One of the most clinically important — and least discussed — aspects of GLP-1 therapy is what happens when the medication is stopped. Multiple studies have shown that a significant proportion of weight loss is regained within 12 months of discontinuation. The STEP 1 extension study showed that participants who stopped semaglutide regained approximately two-thirds of their weight loss within one year.

This is not a failure of the medication or the patient — it reflects the underlying biology. GLP-1 agonists work by overriding the body's regulatory set point for hunger and energy storage. When the medication is removed, those regulatory signals return. Obesity is increasingly recognised in clinical guidelines as a chronic disease requiring long-term management — not a condition to be "cured" with a short course of medication.

For patients and clinicians, this means conversations about GLP-1 therapy should include an honest discussion of long-term plans from the outset. Is this intended as a short-term intervention to reach a weight goal, with the understanding that maintenance strategies will be needed? Or as a long-term medication, similar to antihypertensives? Both approaches are valid — but approaching it without a plan is not.^[8]

Summary

GLP-1 receptor agonists represent a genuine paradigm shift in the pharmacological management of obesity. They work through a multi-faceted mechanism that operates on appetite, satiety, gastric emptying, and blood sugar simultaneously — producing weight loss outcomes previously only achievable surgically, alongside meaningful cardiovascular, metabolic, and organ-protective benefits.

They are also prescription medications with a real side effect profile, important contraindications, and a weight regain dynamic that necessitates long-term thinking. Getting the most from GLP-1 therapy means combining the medication with adequate protein and resistance training to preserve lean mass, a clinician who monitors and adjusts the protocol appropriately, and a realistic plan for long-term weight management.

The science behind these drugs is some of the most compelling in modern pharmacology. But no drug — however effective — replaces the broader clinical context in which it is prescribed.